Hanmi Pharm Group Shareholders' Meeting... Woo Jong-su Reappointed as CEO of Hanmi Pharm

On the 24th, the 12th regular shareholders' meeting is being held at Hanmi Pharm's headquarters in Songpa-gu, Seoul.

[Asia Economy Reporter Lee Gwan-joo] Hanmi Pharmaceutical Group held the 12th regular general meeting of shareholders of Hanmi Pharmaceutical and the 49th regular general meeting of shareholders of its holding company Hanmi Science at its headquarters in Songpa-gu, Seoul on the 24th.

Hanmi Pharmaceutical reported its business performance for last year, including sales of 1,203.2 billion KRW, operating profit of 125.4 billion KRW, and net profit of 81.5 billion KRW, and approved the agenda items presented that day: the appointment of inside directors Woo Jong-su and Lee Gwan-soon, outside directors Kim Pil-gon and Hwang Sun-hye, the appointment of audit committee members, and approval of the director remuneration limit.

At the subsequent Hanmi Science shareholders' meeting, the company reported key business results for last year, including sales of 950.2 billion KRW, operating profit of 58.9 billion KRW, and net profit of 42.9 billion KRW, and approved the agenda items: the appointment of outside directors Kwak Tae-sun, Shin Yoo-chul, and Kim Yong-duk, the appointment of audit committee members, and approval of the director remuneration limit.

Following the shareholders' meetings, the Hanmi Pharmaceutical board of directors approved the reappointment of inside director Woo Jong-su as CEO of Hanmi Pharmaceutical.

Hanmi Pharmaceutical Group stated, “Based on the firm management philosophy of respecting humanity and creating value, we are making our best efforts to address diseases that threaten human life,” and added, “We will focus all of the company’s capabilities to establish ourselves as a global leading healthcare company and return high corporate value to our shareholders.”

The company explained that this shareholders' meeting was conducted in strict compliance with government quarantine guidelines to prevent the spread of COVID-19, and that shareholder opinions were actively collected remotely through the use of electronic voting systems.